Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study

BACKGROUND Gonorrhoea is a major global public health problem that is exacerbated by drug resistance. Effective vaccine development has been unsuccessful, but surveillance data suggest that outer membrane vesicle meningococcal group B vaccines affect the incidence of gonorrhoea. We assessed vaccine effectiveness of the outer membrane vesicle meningococcal B vaccine (MeNZB) against gonorrhoea in young adults aged 15-30 years in New Zealand. METHODS We did a retrospective case-control study of patients at sexual health clinics aged 15-30 years who were born between Jan 1, 1984, and Dec 31, 1998, eligible to receive MeNZB, and diagnosed with gonorrhoea or chlamydia, or both. Demographic data, sexual health clinic data, and National Immunisation Register data were linked via patients' unique personal identifier. For primary analysis, cases were confirmed by laboratory isolation or detection of Neisseria gonorrhoeae only from a clinical specimen, and controls were individuals with a positive chlamydia test only. We estimated odds ratios (ORs) comparing disease outcomes in vaccinated versus unvaccinated participants via multivariable logistic regression. Vaccine effectiveness was calculated as 100×(1-OR). FINDINGS 11 of 24 clinics nationally provided records. There were 14 730 cases and controls for analyses: 1241 incidences of gonorrhoea, 12 487 incidences of chlamydia, and 1002 incidences of co-infection. Vaccinated individuals were significantly less likely to be cases than controls (511 [41%] vs 6424 [51%]; adjusted OR 0·69 [95% CI 0·61-0·79]; p<0·0001). Estimate vaccine effectiveness of MeNZB against gonorrhoea after adjustment for ethnicity, deprivation, geographical area, and sex was 31% (95% CI 21-39). INTERPRETATION Exposure to MeNZB was associated with reduced rates of gonorrhoea diagnosis, the first time a vaccine has shown any protection against gonorrhoea. These results provide a proof of principle that can inform prospective vaccine development not only for gonorrhoea but also for meningococcal vaccines. FUNDING GSK Vaccines.

[1]  R. Heyderman,et al.  Evidence for Naturally Acquired T Cell-Mediated Mucosal Immunity to Neisseria meningitidis 12 , 2003, The Journal of Immunology.

[2]  H. Kløvstad,et al.  Ecologic Study of Meningococcal B Vaccine and Neisseria gonorrhoeae Infection, Norway , 2016, Emerging infectious diseases.

[3]  K. Seib,et al.  Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development , 2016, Critical reviews in microbiology.

[4]  M. Russell,et al.  Vaccines against gonorrhea: current status and future challenges. , 2014, Vaccine.

[5]  B. Everitt,et al.  Statistical methods for rates and proportions , 1973 .

[6]  Richard T. Gray,et al.  The potential impact of vaccination on the prevalence of gonorrhea , 2015, Vaccine.

[7]  R. Arnold,et al.  Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. , 2011, Vaccine.

[8]  J. Sadoff,et al.  Efficacy trial of a parenteral gonococcal pilus vaccine in men. , 1991, Vaccine.

[9]  K. Holmes,et al.  Influence of study population on the identification of risk factors for sexually transmitted diseases using a case-control design: the example of gonorrhea. , 2004, American journal of epidemiology.

[10]  M. Unemo,et al.  Time to clearance of Chlamydia trachomatis RNA and DNA after treatment in patients coinfected with Neisseria gonorrhoeae – a prospective cohort study , 2016, BMC Infectious Diseases.

[11]  M. Virji.  Pathogenic neisseriae: surface modulation, pathogenesis and infection control , 2009, Nature Reviews Microbiology.

[12]  N. Low,et al.  Co-infection with gonorrhoea and chlamydia: how much is there and what does it mean? , 2003, International journal of STD & AIDS.

[13]  X. Nassif,et al.  Analysis of the genetic differences between Neisseria meningitidis and Neisseria gonorrhoeae: two closely related bacteria expressing two different pathogenicities. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R. Rappuoli,et al.  Emerging experience with meningococcal serogroup B protein vaccines , 2017, Expert review of vaccines.

[15]  E. Tramont.  Gonococcal vaccines , 1989, Clinical Microbiology Reviews.

[16]  M. Mayo,et al.  Cytokine and antibody responses in women infected with Neisseria gonorrhoeae: effects of concomitant infections. , 1998, The Journal of infectious diseases.

[17]  R. Rappuoli,et al.  Novel meningococcal 4CMenB vaccine antigens – prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae , 2012, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[18]  Marleen Temmerman,et al.  Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting , 2015, PloS one.

[19]  T. Darville,et al.  Chlamydial Infection Increases Gonococcal Colonization in a Novel Murine Coinfection Model , 2011, Infection and Immunity.

[20]  D. Whiley,et al.  Comparison of the cobas 4800 CT/NG Test with Culture for Detecting Neisseria gonorrhoeae in Genital and Nongenital Specimens in a Low-Prevalence Population in New Zealand , 2013, Journal of Clinical Microbiology.

[21]  M. Unemo,et al.  Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium , 2017, Nature Reviews Urology.

[22]  Peter G Szilagyi,et al.  Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. , 2010, The Journal of infectious diseases.

[23]  N. Garrett,et al.  Sexually Transmitted Infections in New Zealand Annual Surveillance Report 2001 , 2002 .

[24]  D. Lewis.  Global resistance of Neisseria gonorrhoeae: when theory becomes reality , 2014, Current opinion in infectious diseases.

[25]  D. Lennon,et al.  Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers , 2011, Archives of Disease in Childhood.

[26]  K. Holmes,et al.  Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance - The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014. , 2016, Morbidity and mortality weekly report. Surveillance summaries.

[27]  S. Black,et al.  Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV) , 2013, Human vaccines & immunotherapeutics.

[28]  J. Wasserheit,et al.  The emerging threat of untreatable gonococcal infection. , 2012, The New England journal of medicine.

[29]  J. Zenilman,et al.  Gonorrhoea reinfection in heterosexual STD clinic attendees: longitudinal analysis of risks for first reinfection , 2003, Sexually transmitted infections.

[30]  E. Rosenqvist,et al.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine , 1995, Infection and immunity.

[31]  M. Picot,et al.  Prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium in asymptomatic patients under 30 years of age screened in a French sexually transmitted infections clinic , 2014, European Journal of Dermatology.

[32]  R. Rappuoli,et al.  NadA, a Novel Vaccine Candidate of Neisseria meningitidis , 2002, The Journal of experimental medicine.

[33]  R. Heyderman,et al.  Mucosal immunity in healthy adults after parenteral vaccination with outer-membrane vesicles from Neisseria meningitidis serogroup B. , 2008, The Journal of infectious diseases.

[34]  A. Jerse,et al.  Vaccines for Gonorrhea: Can We Rise to the Challenge? , 2011, Front. Microbio..

[35]  J. Barnett,et al.  Holes in the safety net? Assessing the effects of targeted benefits upon the health care utilization of poor New Zealanders. , 2000, Health & social care in the community.

[36]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .

[37]  C. P. Kenny,et al.  Gonococcal vaccine studies in Inuvik. , 1974, Canadian journal of public health = Revue canadienne de sante publique.